Two Sigma Securities’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,700
Closed -$864K 3560
2024
Q1
$864K Buy
4,700
+2,200
+88% +$419K 0.01% 1223
2023
Q4
$450K Buy
+2,500
New +$389K ﹤0.01% 1633
2023
Q2
Sell
-1,900
Closed -$320K 3249
2023
Q1
$320K Buy
+1,900
New +$339K 0.01% 1637
2022
Q4
Sell
-3,600
Closed -$674K 3152
2022
Q3
$674K Buy
+3,600
New +$759K 0.02% 869
2022
Q2
Sell
-3,000
Closed -$564K 2749
2022
Q1
$564K Buy
+3,000
New +$570K 0.02% 918
2020
Q1
Sell
-3,600
Closed -$333K 2126
2019
Q4
$333K Buy
+3,600
New +$302K ﹤0.01% 1724

Other funds holding RGEN

Two Sigma Securities's RGEN Position: Q1 2026 in Review

Two Sigma Securities sold out of Repligen (RGEN) in Q1 2026, closing a stake of 5,226 shares — an estimated $856K sold.

Two Sigma Securities first reported a position in RGEN in Q4 2018 and held it in 12 quarters. The position peaked at $1.58M in Q3 2024. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • Two Sigma Securities reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 5,226 Repligen shares in Q1 2026, an estimated $856K.
  • Two Sigma Securities first reported a position in Repligen in Q4 2018 and held it in 12 quarters.
  • Two Sigma Securities's Repligen position peaked at $1.58M in Q3 2024.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.